Brief: Inflarx Announces Presentation Of New Clinical Data With Lead Candidate Ifx-1 In Hidradenitis Suppurativa
06/02/2019 12:09
Feb 6 (Reuters) - Inflarx NV IFRX.O :
* INFLARX ANNOUNCES PRESENTATION OF NEW CLINICAL DATA WITH
LEAD
CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA
* INFLARX NV - RETROSPECTIVE LONG-TERM RESULTS FROM PHASE
IIA
TRIAL INDICATE SUSTAINED REMISSION POST IFX-1 TREATMENT
* INFLARX NV - BASELINE CHARACTERISTICS FROM ONGOING PHASE
IIB
SHINE TRIAL IN LINE WITH EXPECTATIONS; ON TRACK FOR TOPLINE
RESULTS Q2 2019
Source text for Eikon: ID:nGNX3zVPqN
Further company coverage: IFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum